NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy-Reference-Cited by-同舟云学术

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

Published:2023-12 Issue:12 Volume:4 Page:101329
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Hurtado-Navarro Laura,Cuenca-Zamora Ernesto José,Zamora Lurdes,Bellosillo Beatriz,Such Esperanza,Soler-Espejo Eva,Martínez-Banaclocha Helios,Hernández-Rivas Jesús M.,Marco-Ayala Javier,Martínez-Alarcón Laura,Linares-Latorre Lola,García-Ávila Sara,Amat-Martínez Paula,González Teresa,Arnan Montserrat,Pomares-Marín Helena,Carreño-Tarragona Gonzalo,Chen-Liang Tzu Hua,Herranz María T.,García-Palenciano Carlos,Morales María Luz,Jerez Andrés,Lozano María L.,Teruel-Montoya Raúl,Pelegrín Pablo^ORCID,Ferrer-Marín Francisca

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference58 articles.

1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data;Arber;Blood,2022

2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms;Khoury;Leukemia,2022

3. Molecular basis of myelodysplastic/myeloproliferative neoplasms;Reiter;Haematologica,2009

4. Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2 , CBL , RAS , and RUNX1;Kohlmann;J. Clin. Oncol.,2010

5. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis;Carr;Nat. Commun.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the Nexus of NLRP3 Inflammasomes and COVID-19 Pathogenesis: Unraveling Molecular Triggers and Therapeutic Strategies;Viruses;2024-01-31